JIMD Reports (Mar 2021)

SLC37A4‐CDG: Second patient

  • Matthew P. Wilson,
  • Dulce Quelhas,
  • Elisa Leão‐Teles,
  • Luisa Sturiale,
  • Daisy Rymen,
  • Liesbeth Keldermans,
  • Valérie Race,
  • Erika Souche,
  • Esmeralda Rodrigues,
  • Teresa Campos,
  • Emile Van Schaftingen,
  • François Foulquier,
  • Domenico Garozzo,
  • Gert Matthijs,
  • Jaak Jaeken

DOI
https://doi.org/10.1002/jmd2.12195
Journal volume & issue
Vol. 58, no. 1
pp. 122 – 128

Abstract

Read online

Abstract Recently, a disorder caused by the heterozygous de novo c.1267C>T (p.R423*) substitution in SLC37A4 has been described. This causes mislocalization of the glucose‐6‐phosphate transporter to the Golgi leading to a congenital disorder of glycosylation type II (SLC37A4‐CDG). Only one patient has been reported showing liver disease that improved with age and mild dysmorphism. Here we report the second patient with a type II CDG caused by the same heterozygous de novo c.1267C>T (p.R423*) mutation thereby confirming the pathogenicity of this variant and expanding the clinical picture with type 1 diabetes, severe scoliosis, and membranoproliferative glomerulonephritis. Additional clinical and biochemical data provide further insight into the mechanism and prognosis of SLC37A4‐CDG.

Keywords